Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Multiple Allele Traits01:49

Multiple Allele Traits

The Concept of Multiple Allelism
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biologic modulation of ineffective erythropoiesis in thalassemia: mechanisms, clinical practice, and future targets.

Expert opinion on biological therapy·2026
Same author

Addressing Obstetric and Gynecologic Needs in Thalassemia.

O&G open·2026
Same author

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
Same author

Efficacy and Safety of Tocilizumab in Rheumatoid Arthritis Patients in the Middle East: Real-world Data.

Current rheumatology reviews·2026
Same author

EHA Recommendations for preconceptual and antenatal screening and prenatal diagnosis for hemoglobinopathies.

HemaSphere·2026
Same author

When cure exists but access does not.

Nature medicine·2026
Same journal

What population-based databases reveal about equity in access to hematopoietic cell transplant and cellular therapy.

Blood reviews·2026
Same journal

A tale of two sites - Distinct spatial differences between bone marrow and extramedullary AML.

Blood reviews·2026
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

Thalassemia and hypercoagulability.

Ali T Taher1, Zaher K Otrock, Imad Uthman

  • 1Hematology-Oncology Division, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. ataher@aub.edu.lb

Blood Reviews
|May 31, 2008
PubMed
Summary
This summary is machine-generated.

Beta-thalassemia patients, especially those with thalassemia intermedia, face a high risk of blood clots due to a hypercoagulable state. This review explores the causes and prevention strategies for thrombosis in thalassemia.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Related Experiment Videos

Last Updated: Jul 4, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Area of Science:

  • Hematology
  • Genetics
  • Vascular Medicine

Background:

  • Thalassemia is a congenital hemolytic anemia due to defective globin synthesis.
  • Improved life expectancy in beta-thalassemia patients reveals persistent complications.
  • Thromboembolic events are a significant concern, particularly in beta-thalassemia intermedia.

Purpose of the Study:

  • To review molecular and cellular mechanisms of hypercoagulability in beta-thalassemia.
  • To focus on the high thrombotic risk in beta-thalassemia intermedia.
  • To discuss prophylaxis recommendations for thrombosis in these patients.

Main Methods:

  • Literature review of molecular and cellular mechanisms.
  • Analysis of incidence of thrombotic events across thalassemia types.
  • Synthesis of current recommendations for thrombosis prophylaxis.

Main Results:

  • Beta-thalassemia is associated with a hypercoagulable state.
  • Thalassemia intermedia exhibits the highest incidence of thrombotic events.
  • Understanding mechanisms is crucial for targeted prophylaxis.

Conclusions:

  • Hypercoagulability is a key complication in beta-thalassemia, especially intermedia.
  • Further research into molecular mechanisms can guide preventative strategies.
  • Prophylaxis recommendations are essential for managing thrombotic risk.